U.S. stocks are pushing higher out of the gate this morning. Among specific stocks in focus are iPhone maker Apple Inc. (NASDAQ:AAPL), mobile camera specialist GoPro Inc (NASDAQ:GPRO), and home furnishings retailer RH (NYSE:RH). Here's a quick look at what's boosting shares of AAPL, GPRO, and RH.

Warner Music Deal Fails to Boost Apple Stock

GoPro stock has jumped 21% today to trade at $10.78, after the company gave an upbeat current-quarter outlook. The shares briefly traded in double-digit territory early last month, and quickly retreated, but found support at their 50-day moving average. Of course, the equity remains far removed from its 52-week high of $17.68 from last October. 

But if GPRO can turn things around on the fundamental and technical fronts, there's plenty of room for a round of bullish analyst attention. Specifically, just one of 11 covering brokerage firms recommends buying the security, so upgrades could be in store. 

RH stock is exploding higher this morning, last seen 46% higher at $72.31, thanks to the company's strong quarterly results and upbeat full-year outlook. A handful of analysts have already weighed in, including Buckingham Research, which upgraded the shares to "buy" from "neutral," and raised its price target to $88 from $46. While RH is now up more than 133% year-to-date, it's still staring up at its July 20 peak of $79.91. 

But if short sellers continue to cover, it could help the shares retake those highs. For example, short interest dropped almost 20% in the last two reporting periods, though one-third of the stock's float is still dedicated to short interest. This leaves ample room for the short-covering trend to continue, which could provide tailwinds for RH. 

Analysts are weighing in on car manufacturer Ferrari N.V. (NYSE:RACE), airline stock Spirit Airlines Incorporated (NASDAQ:SAVE), and travel site Trivago NV - ADR (NASDAQ:TRVG). Here's a quick roundup of today's bearish brokerage notes on shares of RACE, SAVE, and TRVG.

Morgan Stanley Downgrade Stalls Ferrari Stock

Ferrari shares are down 5.8% to trade at $110.06, after Morgan Stanley double downgraded the car stock to "underweight" from "overweight" -- citing "valuation concerns" and threats from rivals. RACE stock has been on fire over the past 12 months, up 121% year-over-year thanks to solid support from its 50-day moving average, and setting a new record high of $118.10 yesterday. However, considering the stock's 14-day Relative Strength Index (RSI) closed last night at 71 -- in "overbought" territory -- a short-term breather may have been in the cards.

Sector Weakness, Price-Target Cut Grounds Spirit Airlines

Spirit Airlines stock is down 1.4% to trade at $31.65, after Imperial Capital cut its price target to $32 from $42. This follows a string of negative analyst attention the security has received in recent weeks, and comes as the threat of Hurricane Irma drags the entire airline sector down. In fact, SAVE stock fell to a four-year low of $30.32 yesterday, and the shares have shed over 45% year-to-date. 

It's likely short sellers have had a hand in the equity's recent selloff, too. Short interest surged 40% in the two most recent reporting periods to 4.22 million shares -- the most since mid-December.

Lowered Guidance Leads to a Downgrade for Trivago Stock

Trivago stock is down 2.3% to trade at $12.21, after the company's dismal guidance on Wednesday prompted a downgrade to "neutral" from "buy" at BofA-Merrill Lynch this morning. In addition, the stock received three price-target cuts, including one to $13 from $18 at Cowen and Company. TRVG stock fell to a record low of $10.43 yesterday, breaching its $11 IPO price for just the third time since going public last December. With four analysts still maintaining a "buy" or better rating at last night's close, more downgrades could be on the horizon for the security.

With earnings season all but over, all eyes will be on next week's batch of economic data ahead of the September Fed meeting. And while expectations are low that the central bank will pull the trigger on a rate hike this time around, inflation data in the form of the producer price index (PPI) and consumer price index (CPI) will likely draw increased scrutiny. Retail stocks will also be in the spotlight, with monthly sales data due on Friday.

Below is a brief list of some key market events scheduled for the upcoming week. All earnings dates listed below are tentative and subject to change. Please check with each company's respective website for official reporting dates.

The economic and earnings calendars are bare on Monday, Sept. 11. The Labor Department's Job Openings and Labor Turnover Survey (JOLTS) is the lone economic report on Tuesday, Sept. 12, while the earnings docket is empty.

The PPI and weekly crude inventories update will be released on Wednesday, Sept. 13, along with the Treasury budget. United Natural Foods (UNFI) will take its late-season turn in the earnings confessional.

Inflation data continues to roll in on Thursday, Sept. 14, with the release of the CPI. Weekly jobless claims are also due. Oracle (ORCL) will report earnings.
 
Quadruple witching expiration hits the Street on Friday, Sept. 15, when futures and options on indexes and stocks simultaneously expire. Retail sales and industrial production are also on tap, as is the Empire State manufacturing survey, business inventories, and the University of Michigan consumer sentiment survey. There are no earnings reports of note.

U.S. stocks are mixed this afternoon, with traders taking a cautious approach as Hurricane Irma charts an uncertain path toward Florida. Among the stocks in the spotlight today are biopharmaceutical company Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), bookseller Barnes & Noble, Inc. (NYSE:BKS), and fitness device maker Fitbit Inc (NYSE:FIT). Here's a quick look at what's moving shares of ALNY, BKS, and FIT.

Alnylam Stock Suffers After Drug Setback

Alnylam Pharmaceuticals stock is down 13.9% to trade at $74.08, after a patient's death prompted the drugmaker to stop administering fiturisan, a bleeding disorder treatment, in a clinical trial. This comes a year after Alnylam discontinued a drug for a rare hereditary disease over patient safety concerns. The company expects to resume clinical studies for the suspended drug, named fitusiran, by late 2017. Still, the biotech stock is up roughly 98% year-to-date after hitting an annual high of $89.45 last Friday.

Shorts are likely cheering today's decline, as short interest represents 12% of ALNY's total available float. At the equity's average daily trading volume, it would take more than two weeks to cover these shorted shares.

Barnes & Noble Stock Falls After Earnings

A wider-than-expected fiscal first-quarter loss has Barnes & Noble stock down 11.1% to trade at $6.98. The book retailer cited lackluster quarterly sales of its Nook reading tablet, which resulted from lower promotional activity. BKS shares have lost roughly 37% this year, and hit a five-year low of $6.25 on June 21, with recent breakout attempts contained by its 120-day moving average.

Option traders on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have upped the bearish ante of late. BKS sports a 10-day put/call volume of 8.43, which ranks in the 94th percentile of its annual range. In other words, options players have bought more than eight times as many puts as calls on BKS in the past two weeks.

Fitbit Stock Soars on Dexcom Collaboration

Just over a week after Fitbit launched its Iconic smartwatch, the company announced its plan to collaborate with Dexcom to develop products to help people better manage their diabetes. The companies call it the Continuous Glucose Monitoring (CGM) experience, and hope to make products available to the public next year.

As a result, FIT shares are trading 11.9% higher at $6.62. Today's jump sent FIT shares to an intraday high of $6.78 -- territory the wearable tech stock hasn't seen since early May. What's more, FIT shares are now poised to close above their 200-day moving average for the first time in a year.

Atlanta-based Equifax Inc. (NYSE:EFX), one of the three major U.S. credit bureaus, said late Thursday that a security breach had exposed the data of up to 143 million Americans -- including Social Security numbers, and in some cases, credit card information. Additionally, CNBC reports that three top executives at Equifax unloaded $2 million in company stock days after the breach occurred, though the officers were said to be unaware of the attack when the transactions were made in early August.

EFX stock is down 13% pre-market, on track to open around $124 -- well below recent support at its 80-day moving average. That drop would leave the shares back at early February levels, and -- barring a rapid recovery in today's trading -- would put EFX on pace for a Friday close beneath its 80-week moving average for the first time since 2011. This longer-term trendline provided key support for Equifax shares during a late-2016 pullback.

Ahead of last night's negative news, relatively few traders had sold EFX short. Short interest accounts for only 1.5% of the stock's float, though there likely won't be an opportunity for shorts to build their positions in the immediate future. An intraday drop of 10% or more would put EFX on the short-sale restricted list, which could translate into heightened interest in the equity's put options.

On that front, Trade-Alert reports that put open interest on EFX currently stands at an annual high, though that translates into a fairly modest accumulation of just 3,285 put contracts for lightly traded Equifax options. And while option premiums were pretty tame as of last night's close, with 30-day at-the-money implied volatility of 14.7% registering in only the 18th annual percentile, it seems safe to assume that EFX implieds will spike today.

With that in mind, traders may want to resist the urge to pile on the bearish bandwagon for EFX in light of today's news. There may be more downside in store for the stock as Wall Street learns additional details about the magnitude and fallout of the data breach, but a potentially rapid increase in the price of EFX put options could make it challenging to reap the maximum benefits of options leverage.

UPDATE, 10:25 AM: With just under an hour of trading in the books, EFX put volume has totaled 4,902 contracts -- already setting a new 52-week high. Also at a new annual high, as expected, is 30-day at-the-money implied volatility, which Trade-Alert pegs at 43.7%. Prior to today's surge, the 52-week high in this metric was 26.0%.

Meanwhile, the 30-day implied volatility skew for EFX options is 38.4%, in the 94th annual percentile. This simply confirms that EFX put options are pricing in considerably steeper volatility expectations than the stock's calls.

The major stock indexes are signaling a lower open for equities. Among specific stocks in focus are grocery name Kroger Co (NYSE:KR), cancer treatment developer Clovis Oncology Inc (NASDAQ:CLVS), and data storage expert Western Digital Corp (NASDAQ:WDC). Here's a quick look at what's boosting shares of KR, CLVS, and WDC. 

Kroger Shares Slide After Earnings

Kroger stock is down 6.4% in pre-market trading, after the company's second-quarter earnings matched expectations. This would be just more of the same for the shares, which settled yesterday at $22.77 -- down 27.3% year-over-year and not far from their June three-year low of $20.46. 

Short sellers have been preparing for more losses, too. During the last two reporting periods, short interest rose by 20.1%. Based on average daily volumes, these bears now control six days' worth of buying power on KR.  

Shares of Clovis Oncology have added 4.4% in electronic trading, thanks to news of positive results from the ARIEL3 study. It's been a wonderful year for the stock, which is up almost 200% at $72.32, though it's cooled some since topping out at $99.45 on July 28. In fact, CLVS has been trading below its 50-day moving average since early August. Still, analysts have remained bullish, with six of nine rating the equity a "strong buy." Plus, its average 12-month price target stands up at $91.09. 

Western Digital is in focus this morning amid reports the company is trying to team up with Apple in its bid for Toshiba's chip unit. Over the past year, WDC shares have rallied almost 66%, last seen trading at $88.42. Whether you're expecting a pullback or extended upside, it's a good time to speculate on Western Digital with short-term options. That is, the stock has a Schaeffer's Volatility Index (SVI) of 33%, which sits just 13 percentage points from a 52-week low, hinting at lower-than-usual volatility expectations for near-term contracts. 

Analysts are weighing in on biotech NewLink Genetics Corp (NASDAQ:NLNK), fuel cell specialist FuelCell Energy Inc (NASDAQ:FCEL), and tech stock GoPro Inc (NASDAQ:GPRO). Here's a quick roundup of today's bullish brokerage notes on shares of NLNK, FCEL, and GPRO.

Jefferies Thinks It's Time to Buy NLNK Stock

Jefferies upgraded NewLink Genetics stock to "buy" from "hold" and boosted its price target to $26 from $7. This follows Thursday's nearly 75% surge in NLNK shares on positive data on the combination melanoma treatment, with the brokerage firm expecting "additional upside" for the stock. Based on last night's close at $13.60, Jefferies new price target for Newlink stock represents expected upside of 91%, and sits in territory not seen since February 2016.

With NLNK up an additional 4.7% today to trade at $14.44 -- bringing its year-to-date advance to 40.5% -- short sellers are likely feeling the heat. More than 28% of the equity's float is sold short, or 16.5 times the average daily pace of trading.

FCEL Stock Can't Capitalize on Upbeat Analyst Note

FuelCell Energy saw its price target raised to $2.50 from $2.00 at Cowen and Company, a level the stock has not traded near since last November and higher than the average 12-month price target of $2.38. Nevertheless, FCEL stock is down 1.3% to trade at $1.50, widening its 2017 deficit to 14.3%. What's more, the shares are at risk of falling back below their 40-week moving average, after last week notching their first close north of here since June 2016.

GPRO Stock Rally Fizzles Out

GoPro shares gapped more than 19% higher on Thursday thanks to the company's strong guidance, closing back in double-digit territory. The stock is down 1.1% today at $9.89, however, despite price-target hikes from Morgan Stanley (to $9.50) and Citigroup (to $10.50).

The shares are up 13.5% year-to-date, and GPRO options traders have been pricing in even more upside. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 10-day call/put volume ratio of 2.69 ranks in the 75th annual percentile, meaning calls have been bought to open over puts on GoPro stock at a faster-than-usual pace.

Analysts are weighing in on burrito chain Chipotle Mexican Grill, Inc. (NYSE:CMG), healthcare firm GlaxoSmithKline plc (ADR) (NYSE:GSK), and gun maker American Outdoor Brands Corp (NASDAQ:AOBC). Here's a quick roundup of today's bearish brokerage notes on shares of CMG, GSK, and AOBC.

Chipotle Stock Heads Toward Lowest Weekly Close Since 2013

Chipotle Mexican Grill stock is down 4.4% to trade at $303.36, after Cowen and Company downgraded the shares to "underperform" from "market perform," and slashed its price target by $120 to $250 --- 34% below the average 12-month price target of $381.68. The brokerage firm said perception of quality in its proprietary survey was at levels not seen since the restaurant's food safety catastrophe in late 2015.

It's been an ugly stretch for CMG stock, which has shed 39% since hitting an annual high of $499 in mid-May. This is just the latest in a string of negative analyst notes, too, and today's drop today has the shares on track for their lowest weekly close since January 2013.

Nevertheless, in the options pits, long calls have been unusually popular of late. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), CMG sports a 10-day call/put volume ratio of 1.46, which ranks 3 percentage points from an annual high. 

Morgan Stanley Thinks SNY is More Attractive Than GSK

GlaxoSmithKline stock is down 0.6% to trade at $39.90, after Morgan Stanley downgraded the pharma name to "underweight" from "equal weight " and cut its price target to $20 from $22, saying rival Sanofi (SNY) is more attractive at the moment. After forming a top near $44.50 in June, GSK stock pulled back to the $38.60 region. The shares recently bounced from here, but are now struggling against the round $40 mark. Most analysts are upbeat on GSK, though, with five of nine covering brokerages rating it a "strong buy."

Earnings Miss Prompts Price-Target Cuts For AOBC

American Outdoor Brands stock is down 15.2% to trade at $14.34 -- earlier hitting a two-year low of $13.78 -- after the company reported earnings that fell short of expectations, and lowered its full-year forecast. As a result, no fewer than four brokerages cut their price targets on the gun stock, including Craig-Hallum to $15 from $23.

Today's negative price action is nothing new for AOBC stock, which has shed 31.9% year-to-date, and is now 50% off its 52-week high of $28.57 -- tagged on Nov. 8, the day of the U.S. presidential election. More recently, the shares have been unable to capitalize on a round of short covering, with short interest down 17.7% in the two most recent reporting periods. This points to underlying weakness in AOBC shares.

U.S. stocks are mixed this afternoon, with the Dow pacing for a weekly loss as investors brace for Hurricane Irma's weekend landfall in Florida. Goldman Sachs put three online entertainment stocks in the spotlight today when the brokerage firm initiated coverage on video game titans Activision Blizzard, Inc. (NASDAQ:ATVI), Electronic Arts Inc. (NASDAQ:EA), and Take Two Interactive Software Inc (NASDAQ:TTWO). Here's a quick look at how the analyst attention is moving shares of ATVI, EA, and TTWO.

A Rare "Neutral" Note for Activision Blizzard Stock

Goldman Sachs initiated coverage on Activision Blizzard with a "neutral" rating and set its price target at $65. ATVI shares are off 0.6% at $65.47 -- nearly flat with Goldman's target, but not too far off from last Thursday's record high of $66.58.

The internet gaming stock has gained 81.3% this year, guided higher by support at its 10-week moving average. Activision stock's steady uptrend has been rewarded with predominantly bullish analyst attention, with 17 "buy" or better ratings compared to only one "sell" rating.

Electronic Arts Stock Added to Goldman's Conviction List

Electronic Arts stock is off 0.3% to trade at $118.56, after Goldman Sachs started coverage with a "buy" rating and named the software stock to its Americas Conviction list. The brokerage firm also set its price target on EA to $136 -- well above last Thursday's record high of $122.79.

Electronic Arts stock has climbed roughly 48% over the past year, extending a longer-term uptrend dating back to 2013. Near-term options traders, however, are favoring puts over calls, as evidenced by the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.49 -- in the 80th percentile of its annual range. 

TTWO Touches Second Consecutive Record High

Also scoring a new "buy" rating from Goldman Sachs is Take Two Interactive Software, with the stock up 0.2% at $99.72, after hitting a record high of $100.59 earlier. Today marks TTWO's second consecutive record high, with the shares gaining steady ground in the wake of an early August bull gap. Goldman Sachs also set its price target for the software stock at $118 -- in uncharted territory.

Now up more than 133% year-over-year, TTWO has rewarded options traders by consistently exceeding volatility expectations. The stock's Schaeffer's Volatility Scorecard (SVS) stands at 91, which means TTWO has a strong tendency to make bigger moves on the charts than its options have priced in.

After closing higher for two straight weeks, U.S. stock markets slipped during the holiday-shortened week -- although this is par for the course for the S&P 500 Index (SPX) after Labor Day. Traders returned from the long weekend to react to news of another North Korea missile launch -- with the potential for another strike this weekend -- while anxiety was also heightened by uncertainty surrounding Hurricane Irma. The Category 4 storm is expected to make landfall in Florida on Sunday --with Hurricane Harvey still fresh on traders' minds.

Irma Levels Insurance, Travel Stocks

In addition to the broader equities market, the anticipation surrounding Hurricane Irma took its toll on several sectors. Following last week's selloff for Dow stock Travelers, several other insurance stocks took it on chin, including HCI Group, Universal Insurance Holdings, and Heritage Insurance Holdings -- all of which have heavy exposure to Florida. Several restaurant stocks also took a hit on expectations of shrinking sales, with Fiesta Restaurant shares sinking to multi-year lows.

The travel sector also stared down hurricane headwinds with several cruise stocks selling off, while disappointing guidance only added to United Continental's bad week. Elsewhere, online travel name Priceline -- which is historically the worst stock to own in September -- continued to struggle against newfound technical resistance, due in part to sector peer Trivago's really bad week.

Equifax Breach Lifts Cybersecurity Stocks

Tech stocks had a rough start to the week, attracting a rare batch of put buyers to Advanced Micro Devices' options pits. Himax Technologies, meanwhile, erased some of its Qualcomm-inspired gains, and is on track to end the week in the red. Not all news was bad news, though, with GoPro stock taking an earnings-induced jump into double-digit territory. Plus, a massive data breach at Equifax had cybersecurity stocks like FireEye ending the week strong, while Goldman Sachs said to buy these video game stocks.

Drug Data Boosts NewLink Genetics, Sarepta Therapeutics

It was another busy week for biotechs, with a regulatory win helping spark a record-setting surge for Cellect Biotechnology stock. NewLink Genetics also gapped higher -- more than doubling in value this week, and putting the squeeze on shorts -- on solid drug data, while Sarepta Therapeutics jumped on solid data for its second Duchenne muscular dystrophy (DMD) treatment. On the flip side, Alnylam Pharmaceuticals plunged following a fatal end to its clinical trial. 

It's an Attractive Time to Purchase Options Hedges

And even though volatility spiked this week -- with the CBOE Volatility Index (VIX) pacing toward a 23% weekly gain -- it's still an affordable time to initiate options hedges against broader stock-market uncertainties. While one trader appears to have taken heed and bought out-of-the-money puts on this large- and mid-cap global ETF, big-money traders have failed to hedge long positions on this favorite ETF trade. Drilling down, there are a number of specific equities with cheap options, including several big-cap defense stocks and this uptrending drink stock.

iPhone 8 Reveal, Inflation Data on Tap

Though earnings season is winding down, there's still plenty of upcoming market-moving events to trade. All eyes will be on Apple next week, when the iPhone 8 is revealed -- with one analyst targeting record highs ahead of the event.

Additionally, bank stocks and gold prices could continue to be in focus as inflation data hits ahead of the Sept. 19-20 Fed meeting. No rate hike is expected this time around, while dovish Fed talk this week has some wondering if the central bank will hold off on raising rates until next year. However, despite this week's decline -- and September's historically bearish bias -- it may not be the best time to sell stocks just yet.

The Dow is poised to make a triple-digit jump this morning. Among specific stocks in focus are drug stocks Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Marinus Pharmaceuticals Inc (NASDAQ:MRNS), and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Here's a quick look at what's boosting shares of TEVA, MRNS, and ACHN. 

TEVA Stock Eyes Major Upside After CEO Announcement

Teva Pharmaceutical stock has been battered for months, falling to a 15-year low of $15.22 last week, before closing Friday at $15.50. The shares are set for a major comeback this morning, however, after the company announced Kaare Schultz as its new CEO. In response, TEVA is ready to open 14% higher.  

If these gains come to fruition, it could be a big day for options traders, as well. For instance, Teva Pharmaceutical has a 10-day call/put volume ratio of 3.04 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Not only does this show call buying has tripled put buying during the past two weeks, but this reading ranks in the 90th annual percentile. 

Marinus Pharmaceuticals is also ready to surge today, thanks to news of upbeat trail results for the company's epilepsy treatment, ganaxolone. This penny stock has been delivering monster gains, rising from a Dec. 30 close of $1.01 to settle Friday at $3.12. And with today's news, the shares are pointed another 51.9% higher. Meanwhile, a number of short sellers threw in the towel at the right time. Short interest on MRNS fell by 30.4% during the last two reporting periods. 

On the other end of the spectrum is Achillion Pharmaceuticals, down 23.6% in pre-market trading. This potential sell-off has been sparked by news Johnson & Johnson subsidiary Janssen Pharmaceutical has ended the two companies' collaboration on a hepatitis C treatment. ACHN stock closed last week at $4.91, well below its perch from this time last year when it traded near $8. 

Achillion is now in danger of negative attention from the brokerage bunch. Specifically, five of the seven analysts tracking the equity say it's a "strong buy," and its average 12-month price target stands at $7.14. Don't be surprised if downgrades and/or price-target reductions could through and pressure the shares further. 

Analysts are weighing in on online restaurant delivery service GrubHub Inc (NYSE:GRUB), cancer treatment specialist Array Biopharma Inc (NASDAQ:ARRY), and mining stock Tahoe Resources Inc (NYSE:TAHO). Here's a quick roundup of today's bullish brokerage notes on shares of GRUB, ARRY, and TAHO.

GRUB Stock Gets Mixed Messages from Credit Suisse

GrubHub stock has been flying up the charts since hitting an annual low of $32.43 in early April, up 73% and fresh off last Thursday's record high of $57.61. Nevertheless, Credit Suisse downgraded the shares to "neutral" from "outperform," although the brokerage firm did raise its price target to $53 from $50.

However, this still represents a discount to Friday's close at $56.08 -- and resides in the same ballpark as the stock's average 12-month price target of $52.89. Although GRUB shares are down 1.5% in electronic trading, they could garner more upwardly revised analyst ratings once they resume their longer-term uptrend.

ARRY Stock Gaps After Fresh Round of Price-Target Hikes

Array Biopharma stock is up 8.2% ahead of the bell, after Cantor, Cowen, and Stifel all raised their respective price targets on the stock to $15 -- representing expected upside of nearly 37% to last week's close at $10.98, and territory not seen since early 2002. The shares are up nearly 25% already this year, but have struggled to break out above the $12 mark, including during last Friday's bull gap in the wake of strong late-stage trial results for its colorectal cancer treatment.

A round of short covering could potentially help the stock topple this pesky technical ceiling. Nearly 16% of ARRY's float is sold short, representing 7.2 times the security's average daily pace of trading.

Credit Suisse Raised Its Rating on TAHO Stock

Tahoe Resources stock is set to jump 35.7% out of the gate, after the Guatemalan Supreme Court reinstated a license to the company's subsidiary, Minera San Rafael, for the Escobal mine -- the world's third-largest silver mine. Adding to the bullish bias is an upgrade to "outperform" from "neutral" from Credit Suisse. TAHO shares gapped lower when the license was initially suspended in early July, and hit a record low of $4.24 on Aug. 29. Longer term, TAHO is down 50% year-to-date, closing Friday at $4.70.

Short sellers have been cashing in their winning bets during this decline, too. Since hitting a record high of 10.28 million shares sold short in early May, short interest on the security is down almost 27%.